Multiple sclerosis (MS) is an immunological disease that causes acute inflammatory lesions
and chronic inflammation in the CNS, leading to tissue damage and disability. As awareness …

The Canadian Multiple Sclerosis Working Group has updated its treatment optimization
recommendations (TORs) on the optimal use of disease-modifying therapies for patients …

Background Multiple sclerosis (MS) is a stressful condition; depression, anxiety, pain and
fatigue are all common problems. Mindfulness based interventions (MBIs) mitigate stress …

Multiple sclerosis (MS) is an autoimmune inflammatory demyelinating central nervous
system disorder that is more common in women, with onset often during reproductive years …

Background The phenotypic presentation of multiple sclerosis (MS) may predict long-term
outcomes and little is known about factors contributing to heterogeneity at MS onset. Given …

The expanding therapeutic arsenal in multiple sclerosis (MS) has allowed for more effective
and personalized treatment, but the choice and management of disease-modifying therapies …

It is well known that a number of autoimmune diseases including multiple sclerosis (MS)
predominantly affect women and there has been much attention directed toward …

The idiopathic inflammatory demyelinating disease (IIDD) spectrum has been investigated
among different populations, and the results have indicated a low relative frequency of …

Objective To assess demographic, clinical, magnetic resonance imaging, and treatment
exposure predictors of time to 3 or 12‐month confirmed disability worsening in clinically …

Evidence suggests that brainstem involvement in multiple sclerosis (MS) is one of the major
predictive factors for future disability. Recent work demonstrates that brainstem pathology is …